Findings from a new meta-analysis focusing on non-referral studies suggest that 5-Aminosalicylic Acid offers little, if any, protection against colorectal cancer in Inflammatory Bowel Disease. In a conversation with AJG Co-Editor Dr. Paul Moayyedi, co-investigators Geoffrey C. Nguyen, MD, PhD, FRCPC and Charles N. Bernstein, MD explain why their findings conflict with previous clinic-based population studies and why 5-ASA should not be prescribed to IBD patients solely for their putative effects against CRC.